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ABSTRACT
The cerebral metabolic rate of oxygen (CMRO2) has been shown to be an early indicator
of hypoxia-ischemia (HI); however, the mechanisms controlling post-HI CMRO2 are not
clear. One potential mechanism is the activation of the adenosine A1 receptor due to
increased adenosine concentrations during the insult. The present study investigated if the
specific adenosine A1 antagonist, DPCPX, would attenuate the typical reduction in
CMRO2 and electrical cortical activity following HI. Measurements of CMRO2 and
electrical cortical activity were obtained on piglets by near-infrared spectroscopy (NIRS)
and amplitude-integrated electroencephalography (aEEG), respectively. The post-HI
measurements of CMRO2 and mean aEEG background voltage were significantly less
depressed in piglets treated with DPCPX than controls (p <0.05). The significant
difference in post-HI CMRO2 and aEEG values between DPCPX-treated animals and
controls suggests that the release of adenosine during HI leads to depressed cerebral
energy metabolism due to the inhibition of neuronal activity.

Keywords:
Near-infrared spectroscopy, cerebral metabolic rate of oxygen, cerebral blood flow,
hypoxic-ischemic encephalopathy, neonate, piglets, DPCPX, electroencephalography,
adenosine, antagonist.
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CHAPTER 1
1.1 Hypoxic-Ischemic Encephalopathy
Perinatal cerebral hypoxic-ischemic encephalopathy (HIE) is the leading cause
of brain injury in term newborns [1]. Cerebral HIE is defined as an acute reduction in
the delivery of oxygen and blood flow to the brain [2]. Approximately 1 out of every
500 term newborns are diagnosed with HIE and, of those, 15 to 20% will not survive
past the neonatal period. Of the survivors, up to 25% will have significant
neurological deficits including cerebral palsy, mental retardation and epilepsy [2, 3].
Perinatal HIE is primarily associated with events during labor/delivery such as breech
extractions, rotational maneuvers, prolonged labor, and acute placental or cord
disturbances. These events result in a loss of cerebral vascular autoregulation, leading
to insufficient cerebral blood flow and ultimately brain injury, depending on the
duration and severity of the ischemic insult [4].
The onset of hypoxia ischemia (HI) does not bring forth immediate brain injury,
rather, there is a delay of approximately 12 to 72 h before any evidence of brain
injury manifests [5]. The realization of this delay has lead to the idea that early
interventions (i.e. hypothermia [6]) during this period could improve neurological
outcome and, consequently, the delay is often termed the “therapeutic window” [4, 7,
8]. Unfortunately, early detection of brain injury in newborns by clinical signs
(discussed in the following section) can be subtle or manifest after the therapeutic
window [7, 9].
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The remaining sections of the chapter will discuss techniques for early detection
of HI in newborns, the biochemistry of HI in early and late phases after onset, and the
connection to brain injury. The chapter will then shift focus to discuss near-infrared
spectroscopy (NIRS) and the techniques developed to measure cerebral blood flow
(CBF) and the cerebral metabolic rate of oxygen (CMRO2). This section will be
followed by a review of previous studies investigating post-HI changes in cerebral
energy metabolism, its relationship to brain injury, and the potential mechanisms
controlling CMRO2 during the reperfusion phase. The chapter will end with an
overview of clinical studies of NIRS applied to the newborn, which is the focus of the
appendix.

1.2 Early Diagnosis and Prognosis
Current methods employed for diagnosis of HIE in newborns are limited due to
the delicate nature of neonatal neurology/physiology. The most commonly used
indicator of birth asphyxia is heart rate abnormality. It has been reported that
abnormal fetal heart rate at birth is well correlated with neurological outcome at 1
year [10]; however, in other cases abnormal heart rate patterns showed no correlation
with cognitive functions [11]. This difference supports the idea of a natural resiliency
in newborns through endogenous protectors (such as oligotrophins) against cell death
[12]. Other diagnostic techniques for assessing HI include low-extended
APGAR/SARNAT scores, the need for resuscitation in the delivery room, and
evidence of severe fetal acidemia [13]. All of these techniques suffer from poor
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specificity and a more precise method of diagnosis of perinatal HI is needed to avoid
unnecessary treatment of healthy newborns [14].

1.3 Biochemical Aspects
To understand the clinical relevance of HIE, we need to investigate its
pathophysiology, particularly how it affects cerebral metabolism, hemodynamics,
biochemistry, and tissue viability.

1.3.1 During Hypoxia-Ischemia
Hypoxia-ischemia is usually initiated by a reduction in oxygen (i.e., hypoxia),
with the onset of ischemia occurring after the loss of autoregulation (i.e. the inability
of the cerebral vasculature to maintain adequate CBF during systemic hypotension).
Because of the lack of sufficient oxygen delivery, HI is typically accompanied by a
compensatory increase in an oxygen independent energy production via anaerobic
glycolysis and the consumption of high-energy phosphates, such as phosphocreatine
(PCr) [15]. However, these alternate energy sources are not sufficient to satisfy
energy demands, resulting in a depletion of adenosine triphosphate (ATP).
Insufficient ATP production will adversely affect many cellular mechanisms.
Of major importance are those processes responsible for cell integrity/structure by
controlling proper ion balance, primarily Na+, Cl- and Ca2+. Inadequate energy supply
results in a large influx of these ions into the cells (efflux of potassium and sodium
ions, an influx of calcium), leading to cellular edema and lysis. The fraction of cells
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that will undergo irreversible membrane injury will ultimately depend on the severity
and duration of HI [8]. In addition, this influx of Ca2+ is believed to initiate other
mechanisms – in particular, the destruction of mitochondrial integrity leading to the
formation of radical oxygen species (ROS) [8] – that ultimately leads to further
cellular damage during the reperfusion phase.

1.3.2 Reperfusion
The return of normal blood flow and oxygen levels to the brain triggers
immediate actions that attempt to restore cellular homeostasis. ATP and PCr levels
are gradually replenished by the return of oxidative metabolism; however, there is
evidence that mitochondrial function is impaired following HI. Studies have shown
that mitochondrial impairment, including depressed respiration, is still occurring 6 h
after HI [16-18]. One study involving a neonatal rat model demonstrated suppressed
mitochondrial respiration up to a few days after HI [17].
Mitochondrial dysfunction is known to play a pivotal role in neurodegeneration during the reperfusion phase by initiating and being a target of oxidative
stress [19, 20]. This effect is greatly exasperated by elevated NO levels, which
combines with O2- to form the highly toxic agent peroxynitrite and inhibits
mitochondrial respiration [17, 18]. Despite its short half-life, peroxynitrite is able to
rapidly diffuse across cell membranes and affect surrounding cells [20]. It also
inactivates enzymes including mitochondrial ATPase, inhibiting mitochondrial
electron transport, which leads to cells inability to sustain homeostasis and eventually
apoptosis [21] (Figure 1).
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Another major event in the neurotoxic cascade during reperfusion is the
release of glutamate. Excessive glutamate opens N-methyl-D-aspartate (NMDA)
receptors causing cells to flood with calcium (Ca2+). Increased Ca2+ activates
inflammatory mediators, generates reactive oxygen species, and increases neuronal
and inducible nitric oxide synthase (nNOS/iNOS), all of which lead to protein and
DNA damage and oxidative degradation of lipids. This begins a chain reaction as
ROS, lipid degradation and NO all enhance glutamate release, leading to further
influxes of Ca2+ in a vicious cycle that ultimately leads to mitochondrial cell death
[22]. The administration of an NMDA receptor antagonist has been shown to improve
mitochondrial respiration and reduce brain injury [23]. The evidence that
mitochondrial impairment precedes delayed brain injury suggests that assessing
mitochondrial function could be used as an early marker of ensuing cellular damage
[16].
These damaging pathways set forth a biochemical cascade leading to cell
death, which usually occurs between 24 and 48 h after HI. Delayed brain injury is
associated with the onset of secondary energy failure as characterized by a crash in
high-energy metabolites despite normal levels of arterial oxygen saturation, blood
pressure and blood glucose [24, 25]. It is also associated with seizure activity and
inflammatory responses [25]. Ultimately, these events lead to mitochondrial swelling,
release of pro-apoptotic proteins, and cell death [26]. Since the cerebral metabolic
rate of oxygen reflects mitochondrial energy production, it could be used to detect
compromised brain function before the onset of secondary energy failure. The
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following section will discuss techniques for detecting altered cerebral energy
metabolism during the critical early reperfusion phase.

Figure 1.1- Pathways associated with cell death in hypoxia ischaemia reperfusion
[8]
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1.4 Current Techniques for Detecting Compromised Brain Function
Evidence of impaired cerebral energy metabolism following HI has been
reported

in

studies

using

magnetic

resonance

spectroscopy

(MRS)

and

electroencephalography (EEG) [27, 28]. With MRS, an increase in lactate
concentration during early reperfusion correlates with insult severity [29-31],
presumably indicating increased anaerobic metabolism. However, the early lactate
peak is transient and has been found to suffer from poor specificity [31]. Magnetic
resonance spectroscopy has also been used to confirm the causal relationship between
impaired oxidative metabolism and delayed brain injury, as evident by the
progressive decline in high-energy phosphates and the concurrent increase in lactate
[15, 24, 32]. However, these changes are not observed until late in the reperfusion
period – i.e., after the therapeutic window. A practical limitation with using MRS for
diagnosis of HIE is the need to transport the newborn to the imaging suite, which may
not be feasible depending on the condition of the patient.
Amplitude-integrated encephalography (aEEG) is increasingly being used in
neonatal intensive care units (NICU) for continuous monitoring of cerebral electrical
activity in critically ill newborns [28, 33]. The presence of hypoxic-ischemic injury
can be determined by specific EEG patterns, including burst suppression, very low
voltages, and an isoelectric/flat trace [34-39]. The limitation of aEEG for early
diagnosis of abnormal brain energy function stems from its poor sensitivity [40].
Normal EEG activity has been documented in newborns with clinical evidence of
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brain death [41] and, conversely, newborns can present a flat trace EEG signal in the
first hours after HI and yet continue to develop normally [41].
The lack of current clinical techniques to diagnose HI within the therapeutic
window has created a need for newer techniques capable of accurately detecting the
onset and severity of brain insult within the critical first hours following birth. The
strong correlation between mitochondrial dysfunction and insult severity suggests that
a non-invasive measure of the cerebral metabolic rate of oxygen (CMRO2) could
improve early prognosis of HIE. The interest in NIRS stems from its portability,
which enables bedside monitoring, and its sensitivity to blood oxygenation, which
can be related to the energy demands of tissue. Section 1.8 will discuss how CMRO2
can be measured by near-infrared spectroscopy (NIRS). This section will be followed
by review of previous studies using NIRS to assess the effects of HI on cerebral
energy metabolism. The last section is a discussion on clinical studies using NIRS to
measure CMRO2 in newborns.

1.5 Near-Infrared Spectroscopy (NIRS)
The relative transparency of tissue to near-infrared light (700-1000 nm),
coupled with the unique absorption properties of oxy and deoxy hemoglobin (HbO2
and HHb, respectively) enable tissue blood oxygenation to be assessed by NIRS [42].
The concentration of endogenous light absorbers, which are referred to as
chromophores, can be determined by the loss of light intensity as light passes through
tissue. Ignoring for the moment the scattering of light in tissue, the change in light
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intensity can be related to the concentration of a chromophore by the Beer-Lambert
Law:
I
A = log 0  = εCL
 I 

(1.1)

where A is the absorption of light as it passes through the medium, C is the
chromophore concentration in the medium, ε is the specific extinction coefficient of
the chromophore, and L is the physical distance that the light travelled. Absorption is
defined as the log of the ratio of light intensity emitted (I0) to the intensity detected
(I). Equation 1.1 can be expanded to account for multiple chromophores, each with its
own specific extinction coefficient:
n

A (λ ) = L ∑ ε i (λ )C i
i =1

(1.2)

where λ is wavelength , εi is the specific absorption of the ith chromophore, and Ci is
the concentration of the ith chromophore. The concentration of each can be
determined by acquiring absorption measurements at multiple wavelengths.

1.5.1 Main Endogenous Chromophores
Although water is a weak absorber of NIR light, its contribution to the overall
absorption is significant because of its large abundance in tissue: 80% in the adult
brain and 85% in the newborn brain [43]. The high absorption of water at
wavelengths greater than roughly 1000 nm sets the upper limit of the NIR spectrum
for probing biological tissue [44]. There are three distinct absorption peaks for water
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within the NIR range at 740, 840 and 925 nm. Although water absorption has not
received nearly the attention of hemoglobin in NIRS studies, its stable concentration
in tissue, particularly brain, and its unique absorption features provides a unique
method of quantifying NIRS measurements, as will be discussed in section 1.7.
Of all of the endogenous NIR chromophores, hemoglobin has the largest
attenuation peak due to its high absorption and concentration [44, 45]. The two most
common forms of hemoglobin are hemoglobin alpha (HbA) and fetal hemoglobin
(HbF). The latter is found in newborns; however, its specific absorption spectrum is
the same as HbA. The physiological and clinical interests in NIRS primarily stems
from the unique absorption spectra of HHb and HbO2 (Figure 1.2). By acquiring
measurements at multiple wavelengths, the difference in absorption spectra between
HHb and HbO2, provides a means of determining each concentration, from which
tissue oxygenation extraction (fraction) (OEF) can be determined:

 



–    1.39 
Arterial O




(1.3)

Analogous to the upper limit placed by water, the strong absorption of
hemoglobin at wavelengths below 600 nm sets the lower limit of the biological
window.

11

Figure 1.2–Absorption spectra of endogenous chromophores
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The absorption spectra of water (H2O), deoxy-hemoglobin (HHb), and oxyhemoglobin (HbO2) within the near-infrared range.
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1.6 In-vivo Spectroscopy
In 1977 the first in vivo study demonstrating the sensitivity of NIRS to brain
oxygenation was performed in an animal model by Jobsis et al. [42]. Subsequent
studies extended this method to human adults [46] and newborn infants [47].
However, the main challenge to in vivo spectroscopy is light scattering. Scattering in
tissue disperses and diverges the transmitted light, reducing the intensity that can be
detected. Scattering has wavelength dependence and alters the linear relationship
between light absorption and the concentration of the chromophores. One method for
characterizing the effects of light scattering in tissue is to modify the Beer-Lambert
Law to account for the non-linear path that scattered light takes through tissue:

A(λ ) = β (λ )ε i (λ )Ci + G(λ )

(1.4)

where β is called the differential pathlength which is much greater than the physical
distance between the light source and detector due to light scattering. The additional
factor G accounts for the attenuation of light in tissue due to scattering [48]. This
equation demonstrated that measuring chromophores’ concentrations requires
removing the effects of losses in absorption due to scattering and determining the
differential pathlength.
The work presented in this thesis uses a NIRS technique referred to as second
derivative spectroscopy to quantify the concentrations of chromophores, as described
by Matcher et al. [44]. Second derivative NIRS relies on the principle that both β and
G have a weak dependence on wavelength. Therefore, if the second derivative of
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equation 1.4 is taken with respect to wavelength, G and any derivative terms with
respect to β will disappear, leaving:

∂ 2ε i (λ )
∂ 2 A(λ )
(
)
=
β
λ
∑i ∂λ2 Ci
∂λ2

(1.5)

Assuming a constant water concentration, the mean pathlength can be
determined using the water features at 740 and 840 nm. Since the HHb absorption
spectrum has a strong characteristic at 770 nm, the water-derived differential
pathlength can be used to calculate the absolute concentration of HHb. This approach
is reasonable in the brain because the water concentration is extremely stable and
only changes a few percent, even after HI [49]. The second main assumption of this
technique is that the tissue volume interrogated is homogeneous, which is reasonable
for newborns since the skull and scalp are relatively thin compared to adults.

1.7 Measuring Cerebral Blood Flow by NIRS
Cerebral blood flow (CBF) can be measured by NIRS by tracking the uptake of
a blood flow tracer into brain tissue. The initial approach used a small transient
change in arterial oxygenation as an endogenous (HbO2) tracer [44, 50-53], and it has
been validated by comparison with CBF measurements obtained with the
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Xenon

tracer clearance technique [54]. However, this method is limited by its poor precision
and sensitivity [50]. An alternative approach is to use the light absorbing dye,
indocyanine green (ICG), as an exogenous contrast agent. Indocyanine green is a
water-soluble tricarbocyanine dye that is strongly protein bound (95%) in blood and
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has a relatively short biological half-life (~5 min). The dye has a unique absorption
spectrum with a peak absorbance around 800 nm. When injected into the blood
stream, it rapidly binds with plasma proteins (albumin or lipoproteins), causing a shift
in its absorption spectrum with a new peak at 805 nm [55]. The first use of ICG for an
NIRS application was by Colacino et al. to study cerebral hemodynamics in ducks
[54]. Indocyanine green has a high safety record in human applications [56-61].
Hope-Ross et al. conducted a safety study of 3149 adult patients suffering from
ophthalmia [62]. They reported that the frequencies of mild, moderate and severe
side effects were 0.15%, 0.2% and 0.05%, respectively. The first application
involving human newborns was by Patel et al. [63], who compared the SO2
manipulation and ICG methods of measuring CBF in newborns, and demonstrated a
strong correlation between the CBF values determined by the two techniques (r =
0.93). However, the requirement of rapid changes in arterial oxygen saturation is
difficult to achieve in newborns. For the HbO2 method, 45% of the measurements
collected did not meet the quality criteria and had to be neglected, as opposed to only
11% for the ICG technique. This is related to the greater precision observed with the
ICG method: 85%, compared to 76% for HbO2.
Cerebral blood flow and other hemodynamic parameters, cerebral blood volume
(CBV) and mean transit time (MTT) can be determined by monitoring the dynamic
change in the brain concentration of ICG following an intravenous bolus injection
[64]. With this approach, which is analogous to dynamic contrast-enhanced
techniques used with computed tomography and magnetic resonance imaging [65],
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the time-varying concentration of ICG in brain is modeled as a linear time-invariant
system:
(

!   ") # $%! & $'$

(1.6)

This equation is more commonly written in its condensed form:
!   · # !  %!

(1.6b)

Where ∗ is the convolution operator, Q(t) and Ca(t) are the amount of ICG in the
brain and arterial blood, respectively (Figure 1.3), F represents cerebral blood flow
and R(t) is referred to as the impulse residue function (Figure 1.4). It represents the
amount of ICG in the brain region at any time t following an idealized bolus injection
of unit concentration. Equation (1.6) indicates that in order to measure F, the timedependent arterial and brain concentration must both be measured. With this
technique, Q(t) is determined by 2nd derivative NIRS and Ca(t) is measured noninvasively by dye densitometry [66]. A deconvolution algorithm can be applied to the
time-concentration data to extract a flow-scaled R(t). Cerebral blood flow is given by
the initial height of the function, since by definition R(t) is initially equal to one, and
the area under the function is equal to CBV. The MTT can be determined by the
central volume principle, i.e., CBV = MTTCBF [67]. Because deconvolution is
extremely sensitive to noise, all data were analyzed using a stable algorithm that was
developed specifically for ICG experiments [66].
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Figure 1.3– Sample Arterial and Tissue ICG concentration curves
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Representative tissue and arterial ICG concentration curves measured with NIRS and
the dye densitogram unit. The peak arterial concentration is approximately 20 times
greater than that of tissue concentration since the cerebral blood volume is about 5%
of the total brain volume.
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Figure 1.4– Sample flow-scaled impulse residue function
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CBF and the area under the curve is CBV.
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1.8 Cerebral Metabolic Rate of Oxygen
The cerebral metabolic rate of oxygen can be determined using the Fick
Principle [68]:
#+%  #, · 

&  

(1.7)

where [O2]a is the arterial oxygen concentration and [O2]v is venous oxygen
concentration, which can be determined using the NIRS measurements of tissue
[HHb]. Since NIRS measures the total blood [HHb], this procedure requires assuming
a relative distribution of blood in arterial, capillary and venous blood compartments:
20%, 10%, and 70% respectively [69]. The venous concentration of oxygen is
determined by:
-./0$1   2

3

4 

1

6
& 3  9 :; 7 1.39
& 43 #,-78

<=
>

 (1.8)

This method has been validated in vivo in newborn piglets by comparison to
CMRO2 derived from directly measuring the oxygenation of venous blood collected
from the superior sagittal sinus. In one study [70], piglets were subject to five cerebral
metabolic states created by different anesthetics. No significant differences were
found between CMRO2 measurements obtained from NIRS venous oxygen
measurements and those obtained from sagittal-sinus blood samples at any anesthetic
level. Across all metabolic conditions, a strong correlation between the two
techniques was found (R2 = 0.88). The same validation approach was used in a
subsequent study to demonstrate the accuracy of the NIRS CMRO2 measurements
following HI [71].
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1.9 Assessing the Effects of Hypoxia-Ischemia on Cerebral Energy
Metabolism by NIRS
There have been several studies that have used NIRS to assess the effects of HI
on cerebral oxygenation and blood flow. Recently, Kurth et al. 2009 [72] investigated
the relationship between HI duration and cerebral oxygen saturation (ScO2) to
establish a viability threshold that predicts neurological outcome. A correlation
between the duration of ScO2 below 35% and neurological outcome was reported,
suggesting that this NIRS measure of injury duration could be used to predict
neurological outcome. In contrast, Ioroi et al 2002 [73] demonstrated in newborn
piglets that ScO2 quickly recovered to baseline values during reperfusion, despite
evidence of reduced brain activity measured by aEEG. The inability to detect post-HI
alternations in brain activity suggests that a more sensitive NIRS marker of cerebral
energy metabolism is required. One approach is to use NIRS to measure CMRO2
using the technique outlined in section 1.8.
Tichauer et al. was the first to use NIRS to investigate potential post-insult
changes in CMRO2 [71, 74, 75]. In an animal model of neonatal HI, CMRO2 was
found to be suppressed after HI and remained significantly depressed compared to
pre-HI values for 6 h. Interestingly, post-HI CBF and [HHb] values between controls
and HI groups were not significantly different after 30 min of reperfusion,
demonstrating the importance of measuring CMRO2 directly. In a subsequent paper,
post-HI suppression in cerebral metabolism was strongly correlated with the duration
of HI at 12 h after the insult [74]. It was postulated that the delay in the correlation
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between insult duration and cerebral metabolism could be attributed to the effects of
anesthesia. In a subsequent study, experiments were repeated using a lighter
anesthetic (fentanyl) and it was shown that the correlation between CMRO2 and HI
was observable 45 min after the insult [75]. It was also demonstrated that a linear
relationship between the mean voltage measured by amplitude-integrated EEG and
CMRO2 existed. This latter result brings up an important question regarding the
mechanisms controlling cerebral energy metabolism following HI: Do the changes in
CMRO2 reflect mitochondrial dysfunction, as discussed above in Section 1.3.2, or do
they reflect a reduction in energy demand due to reduced electrocortical activity, as
suggested by the correlation with EEG [75]?
Understanding the possible mechanisms controlling cerebral energy metabolism
during the reperfusion phase would help assess the value of CMRO2 as a clinical
marker of HI. That is, if metabolic depression observed by NIRS indicates
mitochondrial impairment then it could be used as an early marker of secondary brain
injury. As discussed in Section 1.3.2, the potent effects of NO on mitochondrial
energy production could be involved in the observed CMRO2 suppression post HI
[76]. Not only does elevated NO help to ‘kick start’ the processes leading to delayed
brain injury, it has the immediate effect of inhibiting mitochondrial respiration [20].
Administration of NO inhibitors after HI has been shown to reduce brain injury and
improve energy metabolism [77, 78]. To test whether impaired mitochondrial energy
production is related to suppressed energy metabolism post HI, Winter et al.
examined the relationship between CMRO2 and the high-energy metabolites,
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measured by magnetic resonance spectroscopy. A general recovery of the metabolites
despite reduced CMRO2 was observed during the early recovery period, suggesting
sufficient energy production [79].
Another possible mechanism responsible for decreased CMRO2 following HI is
the increase in extra-cellular adenosine concentration. Adenosine A1 receptors in the
brain are known to greatly influence cerebral synaptic activity by mediating cell
membrane polarization and controlling neuronal firing. During HI, the breakdown of
ATP results in increased concentrations of adenosine and ADP. The accumulation of
extra-cellular adenosine in the brain is known to lead to hyper-polarization of cells,
greatly reducing synaptic activity and therefore depressing the brain’s energy
demands [80]. This may explain the similar reductions in magnitude of post-HI
CMRO2. Recently, an adenosine receptor antagonist was shown to abolish the
metabolic depression during hypoxia in fetal sheep [80]. However, the role of
adenosine following neonatal HI is unclear since adenosine antagonists were shown
to have little effect on the extent of brain injury in neonatal rats [81]. The lack of an
effect in these experiments may have been due to the severity of the hypoxicischemic insult. Clearly, there is a need to better understand the mechanisms
controlling post-HI oxidative metabolism and how they relate to delayed brain injury
considering that changes in CMRO2 are one of the earliest measurable events
following HI. Understanding these adenosine-mediated mechanisms is the focus of
the experiments presented in chapter 3.

1.10 Clinical Applications of NIRS in CBF and CMRO2
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Measurements
An understanding of the rate of oxygen delivery and blood flow in sick infants
undergoing intensive care is an important aim of neonatal diagnostic care. As NIRS is
portable, safe and non-invasive, it is ideal for clinical studies. As early as 1988, one
of the first NIRS studies measured CBF in newborns undergoing indomethacin
treatment for asphyxiation [82]. A sizable reduction in CBF from 18 ml/min/100g to
7 ml/min/100g after treatment was observed due to the vaso-constrictive property of
indomethacin. Bucher et al. validated NIRS CBF measurements by a comparison to
measurements obtained with the
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xenon clearance technique [51]. A similar

comparison was conducted by Skov et al.[83] on newborns, showing that there was a
strong correlation between the two techniques (R2 = 0.84, p < 0.0001). Since these
validation studies, there have been several studies using NIRS to assess CBF in
newborns with neurologic injuries. Meek et al. [84] showed that CBF is significantly
declined in preterm newborns suffering from intraventricular hemorrhages, while
Bellinger et al. [85] observed that newborns showed increased brain perfusion while
undergoing hypothermia treatment during cardiopulmonary bypass surgery. A good
compilation of similar NIRS perfusion studies is given by Chakravarti et al. [86].
Yoxall et al. [87] was the first group to measure cerebral oxygen consumption
(CMRO2) in newborns using NIRS. They were able to show that oxygen metabolism
is linearly related with increasing gestational age and their values were in a good
agreement with values obtained in other more invasive studies. In a subsequent study,
Kissack et al. showed that increased oxygen consumption during the first 3 days after

23

birth indicated increased cerebral activity as result of normal adaptation to
extrauterine life [88]. Elwell et al. [89], reported a good agreement between their
NIRS CMRO2 measurements and previous values obtained with PET [90]. Recently,
Roche et al.[91] followed 56 premature newborns of various gestational age and
showed that relative CBF and CMRO2 correlate better with postnatal age (R= 0.37
and 0.43, respectively) compared to SO2 (R= -0.07). They concluded that, in the
premature newborns, relative CBF and CMRO2 measurements are more accurate
biomarkers of the brain development than SO2. In a follow-up study they
demonstrated that NIRS could be used to measure regional developmental changes in
CBF and CMRO2 in newborns [92], similar to earlier studies using PET [93] and
single-photon emission computed tomography (SPECT) [94].
The majority of these clinical NIRS studies use the HbO2 flow tracer method to
measure CBF, rather than an endogenous dye such as ICG. As mentioned earlier, this
method suffers from poor repeatability and low precision compared to the ICG bolustracking approach. The appendix of this thesis will discuss a study using the
NIRS/ICG technique to measure CBF in preterm newborns undergoing drug therapy
for a common heart condition, patent ductus arteriosus.

1.11 Research Objective
I.

To provide a clearer understanding of the relationship between early changes
in CMRO2 and brain injury, the goal of the present study was to investigate a
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potential mechanism underlying the observed reductions in CMRO2 following
HI. Elevated adenosine levels, as observed during HI, are known to inhibit
synaptic activity and reduce metabolic demand via adenosine A1 receptor.
Studies have shown that blocking these adenosine receptors during hypoxia
(ischemia) with a specific adenosine A1 receptor antagonist, 8-cyclopentyl1,3-dipropylxanthine (DPCPX), diminished the cerebral metabolic depression
during hypoxia. The objective of this study was to investigate if the same
adenosine A1 receptor antagonist affects the CMRO2 and synaptic activity
(aEEG) depression following HI in neonatal piglets.
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CHAPTER 2 - METHODS & MATERIALS
2.1 Animal Preparation
The study was approved by the Animal Use Subcommittee of the Canadian
Council on Animal Care at the University of Western Ontario. Newborn Duroc
piglets were delivered from a local supplier on the morning of the experiment. All
surgical

procedures

were

performed

under

3%

isoflurane.

Piglets

were

tracheotomized and mechanically ventilated on a 2:1 oxygen/medical-air mixture.
Two incisions were made lateral to the trachea, and vascular occluders (In Vivo
Metric, Healdsberg, CA) were placed around both carotid arteries just proximal to the
carotid bifurcation. A cannula was inserted into an ear vein for injecting the NIRS
contrast agent (indocyanine green, ICG) and another cannula was inserted into a belly
vein for infusing 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) and fentanyl. A final
cannula was inserted into a femoral artery for continuous monitoring of blood
pressure and to allow the collection of arterial blood samples for gas and glucose
analysis. Following surgery, isoflurane was reduced to 1.75%, and piglets were
allowed to stabilize for 1h before the experiment started.

2.2 Experimental Procedure
Piglets were randomly divided into two groups: a drug group (i.e. those who
received DPCPX) and a control group (i.e., those who received the vehicle). For the
baseline NIRS measurements of CBF and CMRO2, the anesthetic was switched from
isoflurane to a combination of an i.v. infusion of 0.02 mg/kg/h fentanyl and the
inhalation of 30% oxygen/70% N2O gas mixture. Two measurements were acquired,
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separated by 10 min to allow time for the concentration of ICG in the blood to
equilibrate. The anesthetic was switched to fentanyl/nitrous oxide because this
combination has less of an effect on cerebral metabolism than isoflurane [95].
Following the baseline measurements, isoflurane anesthesia was reinstated for the
hypoxic-ischemic insult to replicate the HI protocol used in our previous studies [71,
74, 75]. After a period of 45 min, a hypoxic-ischemic insult was induced by clamping
both carotid arteries and reducing the fraction of inspired oxygen to 7%. Based on a
threshold established in our previous study, ischemia was defined when the mean
arterial pressure (MAP) fell to less than 70% of baseline [74]. All piglets were then
subjected to 10 min of ischemia, after which the carotid clamps were released and the
fraction of inspired oxygen returned to baseline levels.
For the drug group, DPCPX was infused intravenously for 30 min prior to the
start of HI, discontinued during HI, and then continued again for another 30 min after
the insult had ended. DPCPX infusion was paused during HI as a precaution because
this drug is known to elevate heart rate, which can lead to cardiac arrest during
stressful conditions [96]. DPCPX was prepared in 0.1M NaOH to a concentration of
2.5mg/min with a final pH of approximately 10. The drug was infused at a rate of 2.5
mg/min for the first 10 min and at 0.75 mg/min for the reminder of the infusion
period [80]. The same infusion protocol was followed for the control group using
only the vehicle (no DPCPX). After the hypoxic-ischemic insult, the anesthetic was
again switched from isoflurane to the fentanyl/N2O mixture. After 30 min of
reperfusion, four NIRS measurements of CBF and CMRO2 were collected with each
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measurement separated by at least 10 min to allow time for ICG clearance. EEG data
were collected continuously throughout the study.
At all times during the experiment (excluding the insult), arterial PCO2 was
maintained between 38–42 Torr by adjusting the respiratory rate, and arterial PO2 was
maintained between 100–150 Torr by adjusting the ratio of oxygen to medical air.
Blood glucose was kept between 3 and 8 mmol/l by intermittent 0.3-ml injections of a
25% dextrose solution into an ear vein. A water-heating blanket was used to maintain
a rectal temperature between 37 and 38°C. Arterial pH and heart rate were also
monitored.

2.3 Near-Infrared Spectroscopy
NIRS data were collected with a continuous-wave, broadband (600 –1,000
nm) system with a single emission fiber-optic bundle and a single detection bundle
[66]. The end of each bundle was placed 3 cm apart, parasagittally on the head,
proximal to the widest part of the brain. The bolus-tracking technique for measuring
CBF involved measuring the time-dependent concentration of ICG in arterial blood
and brain tissue following a rapid intravenous injection of the dye (0.1 mg/kg). The
arterial blood ICG concentration curve was measured by a dye densitometer attached
to a front paw and the brain ICG concentration curve by NIRS. Both concentration
curves were acquired over a period of approximately 60 s, and a deconvolution was
applied to the data to extract estimates of CBF, cerebral blood volume (CBV) [66]
and subsequently CMRO2. The exact methods used to calculate CBF and CMRO2 by
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NIRS have been outlined in detail previously [66, 68, 70] and briefly in the
introduction (Chapter 1 Sections 1.7 and 1.8).

2.4 Electroencephalography
To assess electrocortical brain activity, needle electrodes were inserted to
record from the left and right parietal regions of the brain. The signal was recorded at
a sampling rate of 250 Hz after being amplified and filtered (0.1–100 Hz) using a
high-performance AC preamplifier (model P511, Grass Technologies Product Group,
Astro-Med, West Warwick, RI). An algorithm developed in MATLAB (The
MathWorks, Natick, MA) was used to convert the raw EEG data to an aEEG signal
[75]. Data were filtered, rectified, and integrated over a window of 100 ms. To
eliminate non-physiological signal components and to attenuate the dominant deltawave patterns, a series of filters were applied to mimic those used in the Cerebral
Function Monitor [97]. The final signal was plotted logarithmically, and the resulting
aEEG was analyzed by two different methods: a quantitative mean aEEG background
technique and a qualitative neural activity score technique.
The mean aEEG background signal was measured by drawing a line through
the upper and lower margins of the aEEG band, as described by al Naqeeb et al. [37].
In this way, individual spikes separated from the aEEG band are excluded from the
measurement. The median line between the upper and lower margins was taken to be
the mean amplitude. A neural activity score, reflecting the functional state of the
brain, was calculated based on the background voltage and pattern recognition.
Specifically, the background voltage was graded as normal, low, or extremely low.
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The background pattern was classified as either continuous or discontinuous, and the
presence of seizure activity or burst-suppression pattern was noted [98]. The aEEG
data from each experiment were scored in 10-min intervals and then grouped to
calculate a mean neural activity scores for baseline and reperfusion periods.

2.5 Statistical Analysis
SPSS 17.0 (SPSS, Chicago, IL) was used for all statistical analyses. A twoway, mixed analysis of variance (ANOVA) with Bonferroni post-hoc correction was
used to compare measurements between drug and vehicle/control groups, with time as
the within-subjects variable and treatment as the between-subjects variable. The
analysis was conducted for average pre- and post-HI values of CBF, OEF, CMRO2
and EEG. When appropriate, group differences at individual time periods were
investigated by a Student’s t-test. For nonparametric data, such as the neural activity
scores, the Spearman’s rank test was used. Statistical significance for all tests was
based on a P < 0.05. All values are presented as means ± SE.
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CHAPTER 3 - RESULTS
A total of 20 piglets (9 males, 11 females) were studied. Three females in the
drug group could not be revived during HI due to cardiac complications and were
therefore excluded from the results. There were a total of 10 piglets in the drug group
and 7 in the control group (average age: 27 ± 5 h, weight: 1.58 ± 0.06 kg). Table 3.1
summarizes the results of the physiological parameters for each group at baseline and
during reperfusion. No significant differences were found between the two groups for
any of these parameters. Although both groups showed a trend of increased heart rate
after HI, this effect did not reach significance. All other physiological parameters
remained within their normal range.
The duration of ischemia, as defined by MAP below 70% of baseline, was not
significantly different between the two groups: 10 ± 1.58 min for the vehicle group
and 10.92 ± 1.48 min for the drug group. However, the total duration of carotid
clamping and reduced inspired oxygen was significantly longer for the drug group
(25.3 ± 1.45 min) compared to the vehicle group (14.4 ± 1.86 min). This difference
suggests that DPCPX delayed the onset of loss of autoregulation caused by HI.
Figure 3.1 presents average CBF, OEF and CMRO2 values for the drug and
vehicle groups at baseline and during reperfusion. Significant time (p < 0.001) and
treatment effects (p < 0.001) were found for CBF, but no overall time-by-treatment
interaction was observed. Average baseline CBF values for the vehicle and drug
groups were 50.86 ± 3.59 and 60.58 ± 5.67 ml/min/100g, respectively, which were
not significantly different. In both groups, CBF fell by roughly 20% following HI to
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40.55 and 48.5 ml/min/100g for the vehicle and drug group, respectively. Figure 3.1B
presents the average OEF values for the two groups pre- and post-HI. No significant
time or treatment effect was found, nor was there a significant time-by-treatment
interaction.
Figure 3.1C presents the average CMRO2 values for the drug and vehicle
groups at baseline and after reperfusion. A significant time-by-treatment interaction
was found (F(3,66) = 4.81, p < 0.05, power = 0.68) with a significant overall time
effect (p < 0.001). The source of the interaction was the difference in the post-HI
CMRO2 values (p < 0.05), whereas, there was no significant difference between
groups at baseline. Average baseline values were 2.71 ± 0.06 and 2.52 ± 0.12 ml
O2/min/100g for the vehicle and drug groups, respectively. A significant decrease in
CMRO2 was observed for the vehicle group compare to baseline, with an average
post-HI value of 1.88 ± 0.18 ml O2/min/100g (p < 0.001). For the drug group,
CMRO2 decreased to 2.25 ± 0.21 ml O2/min/100g after HI, but this change was not
significant from its baseline value.
Figure 3.2A presents the average aEEG values for both groups at baseline and
during reperfusion. There were overall significant time (p < 0.01) and treatment (p <
0.01) effects, as well as a significant time-by-treatment interaction (F(3,66) = 3.9, p <
0.05, power = 0.70). There was no significant difference in baseline aEEG
measurements between the two groups with average values of 48.5 ± 1.6 and 50 ±
1.52 µV for the vehicle and drug group, respectively. Post-hoc analysis revealed a
significant difference between the two groups following HI (p < 0.01). For both
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groups, aEEG dropped significantly after HI: 34 ± 5.6 µV for the drug group (p <
0.01) and 21.8 ± 4.8 (p < 0.001) for the vehicle group. A significant difference in the
time between the start of HI and the resulting reduction in aEEG activity was also
observed (Figure 3.3). This delay was significantly shorter for the vehicle group (3.67
± 1.03 min) compared to the drug group (15.2 ± 3.97 min).
Figure 3.2B presents the averaged neural score values for the two groups
before and after HI. Significant time (p < 0.001) and treatment (p < 0.001) effects and
a significant time-by-treatment interaction were observed (F(3,66) = 39.7, p < 0.001,
power = 0.86). For piglets in the drug group, the average neural score dropped to 3.3
± 0.4 during the reperfusion period. However, this difference was not significant
compared to baseline. The neural score for the vehicle group dropped significantly to
2.1 ± 0.4 (p < 0.001) during the reperfusion period. An inter-group comparison
showed there was a significant difference in neural scores between the post HI
periods of the 2 groups (p < 0.001).
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Table 3.1 Physiological variables for the drug and vehicle groups before insult
(baseline) and during reperfusion.

Baseline

Post Insult

Vehicle
Drug

Mean Arterial Pressure (Torr)
70.4 ± 1.53
67.67 ± 2.29
65.54 ± 2.46
67.07 ± 2.03

Vehicle
Drug

Heart Rate (beats/min)
197.25 ± 7.47
206 ± 5.82
171.84 ± 10.16
201.24 ± 12.7

Vehicle
Drug

Arterial pCO2 (Torr)
40.18 ± 1.08
39.69 ± 0.66
39.72 ± 0.87
39.53 ± 0.69

Vehicle
Drug

Arterial pO2 (Torr)
123.13 ± 5.23
128.25 ± 2.68
123.36 ± 2.84
122.7 ± 2.63
Arterial pH

Vehicle
7.37 ± 0.05
Drug
7.40 ± 0.04
Values are mean ±SE

7.35 ± 0.03
7.41 ± 0.03
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Figure 3.1 Comparison of (A) cerebral blood flow (CBF), (B) oxygen extraction
fraction (OEF) and (C) cerebral metabolic rate of oxygen (CMRO2) between
treatment (DPCPX) and vehicle groups at baseline and after HI. Error bars represent
SE and * indicates statistical ssignificance.
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Figure 3.2 Comparison of (A) mean amplitude-integrated electroencephalography
(aEEG) and (B) neural scores between treatment (DPCPX) and vehicle groups at
baseline and post HI. Error bars represent SE and * indicates statistical significance (p
< 0.05).
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Figure

3.3

Continuous

amplitude-integrated

electroencephalography

(aEEG)

recording plotted against time for one animal in the treatment (DPCPX) group (A)
and another animal in the vehicle (B). *indicates start of drug/vehicle infusion, **
indicates start of insult conditions and *** indicates the end of insult.
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CHAPTER 4 - DISCUSSION
The brevity of the therapeutic window highlights the need to quickly identify
infants at risk of HIE in order to maximize treatment efficacy [99]. One approach is to
measure cerebral energy metabolism since impaired metabolism has been suggested
as an early marker of delayed brain injury [16]. Our group and others have previously
shown in an animal model of HI that CMRO2 is depressed following an hypoxicischemic insult; however, the mechanisms controlling post-HI CMRO2 were unclear
[71, 74, 77, 78]. The principle finding of the current study was that the administration
of the adenosine A1 receptor antagonist, DPCPX, significantly reduced the metabolic
depression following moderate HI. Considering that adenosine concentrations are
known to rise during HI and have been shown to substantially suppress electrocortical
synaptic activity [100-102], these results suggest that the observed post-HI reduction
in CMRO2 was most likely due to reduced cerebral energy demands. This conclusion
was substantiated by the results from the concurrent aEEG recordings, which
displayed significantly less electrocortical suppression after HI in animals
administered DPCPX.
The role of adenosine in suppressing electrocortical activity and cerebral
energy metabolism under conditions that lead to oxygen deprivation has been
demonstrated in a number of studies. Administrating DPCPX in near-term fetal sheep
undergoing 10 min of umbilical cord occlusion was shown to delay the rapid decline
in EEG intensity that was observed at the beginning of cord occlusion in control
animals [103]. Similarly, the time to electrocortical suppression following global
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cerebral ischemia was significantly longer in rats administered DPCPX [104]. This
specific adenosine A1 receptor antagonist has also been shown to increase the
recovery rate of spontaneous electrocortical activity following transient global
ischemia [105]. Regarding cerebral energy metabolism, Blood et al. showed that
DPCPX completely abolished the reduction in cortical heat production – an indicator
of cortical metabolism [103] – that occurs during cerebral hypoxia [80]. DPCPX
treatment was also found to attenuate the reduction in heat production during cord
occlusion [106]. The results of the current study are in good agreement with these
previous studies. In piglets treated with DPCPX, the suppression of EEG activity
following the onset of HI was delayed by approximately 10 min compared to
controls. Furthermore, post-HI CMRO2 and mean aEEG voltage were significantly
greater in treated animals, although the latter remained below pre-HI values in both
groups. This general agreement suggests that activation of the adenosine A1 receptor
due to the rise in adenosine concentrations during HI is the primary reason for
reduced CMRO2 following an hypoxic-ischemic insult. It is generally considered that
the adenosine-induced reduction in cerebral metabolism is a neuroprotective response
[107, 108]. For instance, Halle et al. demonstrated that enhancing the binding of
adenosine to its A1 receptors resulted in substantially reduced brain injury following
HI in newborn rats [109].
In contrast to the above findings, Jensen et al. reported that treatment with
DPCPX had little to no effect on cerebral metabolism or EEG intensity in fetal sheep
exposed to 10 min of asphyxia [110]. Compared to baseline values, significant
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reductions in EEG intensity and cortical heat production were observed during the
first 4 h after occlusion. One possible reason for the discrepancy between the two
studies could be differences in the severity of asphyxia. The 10-min cord occlusion
model was classified as a severe injury as demonstrated by significant neuronal loss
[111]. In the current study, all piglets were subjected to 10 min of ischemia; however,
the severity of ischemia is likely less than during complete cord occlusion due to
residual blood flow through the vertebral arteries [71]. Furthermore, the correlation
between the degree of neuronal damage, as indicated by the number of Fluoro-Jade B
positive cells, and ischemia duration would indicate that a 10-min insult would likely
be classified as a mild-to-moderate injury [74]. This explanation would also agree
with the reported differences in the effects of DPCPX on cerebral metabolism during
hypoxia [80], which showed attenuation of metabolism post-HI, compared to severe
asphyxia [106] which did not. Another explanation could be the difference in the
DPCPX infusion protocol used in the two studies. With the cord occlusion model, the
DPCPX infusion was stopped at the end of the occlusion period, whereas, in the
current study the infusion was continued for another 30 min. It may be that the
infusion during the early post-HI period was necessary to abolish the effects of
residual adenosine from the hypoxic-ischemic period.
The results of the current study also complement the findings of our previous
study that combined NIRS measurements of CMRO2 with phosphorous (31P) and
proton (1H) magnetic resonance spectroscopy [79]. In that study, a general recovery
of high-energy metabolites and a reduction in lactate concentration in the brain were
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found during the recovery period following 30 min of HI, despite depressed CMRO2.
It was postulated that the discrepancy between CMRO2 and metabolite levels
reflected a reduction in cerebral energy demands following HI rather than impaired
energy production. Similar results were found in the current study as evident by the
concurrent reductions in post-HI aEEG intensity and CMRO2 in the control animals.
Furthermore, the increase in both of these measures in the DPCPX-treated animals
suggests a possible mechanism to explain these findings.
Another potential mechanism contributing to the metabolic changes observed
following HI is nitric oxide. Increased neuronal and inducible nitric oxide synthase
(NOS) expression has been observed during the first 6 h following HI [18, 112], and
it is known that elevated NO levels can reduce mitochondrial respiration by inhibiting
cytochrome c oxidation. [20, 113]. Peeters-Scholte et al. demonstrated in newborn
piglets that the use of selective (neuronal and inducible) NOS inhibitors, following 60
min of HI, reduced brain cell damage and improved the cerebral energy state, as
characterized by the recovery of the concentration of high-energy metabolites
(phosphocreatine and ATP) [77]. Dorrepaal et al. demonstrated in fetal lambs that
infusing a non-selective NOS inhibitor after HI prevented the expected decrease in
CMRO2 and showed a delayed improvement in electrocortical brain activity [78].
One possible link between these studies and the current results is the involvement of
the adenosine A1 receptor in the up-regulation of nitric oxide synthesis and signaling
[114, 115]. Using an in-vitro model of cerebral ischemia, Barth et al. demonstrated
that activation of A1 receptors increased nitric oxide production, which lead to
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increased neuronal damage [116]. Although these results appear to conflict with the
concept that adenosine is a neuroprotector, elevated NO production occurred at
relatively high adenosine concentations (> 10 µM). Further studies involving in-vivo
models could help to better elucidate the potential relationship between adenosine,
nitric oxide synthesis, and cerebral metabolism. One approach would be to measure
markers of elevated NO production in animals treated with DPCPX [76].
In the current study, both the DPCPX group and controls showed a significant
CBF reduction of approximately 20% after HI. Cerebral hypoperfusion has been
reported previously with other animal models of hypoxia-ischemia [117, 118]. The
concurrent reduction in both CBF and CMRO2 in the control group suggests that the
post-HI hypoperfusion is a result of the coupling between CBF and cerebral energy
metabolism. However, there was no increase in CBF in the DPCPX group despite the
significant increase in post-HI CMRO2. Instead, a trend of elevated OEF was
observed, although it did not reach statistical significance. It is difficult to interpret
the CBF results, as we have observed considerable variability in post-HI perfusion
changes in previous studies with both significant hypoperfusion and full recovery
reported [71, 74]. Unlike CMRO2, a significant correlation between CBF and insult
duration was not observed [75].
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CHAPTER 5 - SUMMARY
5.1 Summary
The cascade of events leading to the depression of cerebral oxidative
metabolism after hypoxia-ischemia is complex [7]. The present study demonstrates
that blocking the adenosine A1 receptor significantly diminished the depression of
CMRO2 and aEEG typically observed following HI. These results suggest that postHI cerebral energy metabolism is at least, in part, controlled by an adenosinemediated mechanism. These results complement earlier studies showing similar
effects in the fetal brain during hypoxia. However, more studies are required to
determine if this mechanism has a role following more severe hypoxia-ischemia and
if these changes are ultimately related to the final extent of brain injury.

5.2 Limitations
5.2.1 Limitations of the Near-Infrared Spectroscopy Cerebral
Metabolic Rate of Oxygen Measurement
There are three primary limitations to the NIRS method described for
measuring CMRO2. The most important is the assumption that the relative arterial and
venous fractions of the cerebral blood volume are known. NIRS measurements cannot
distinguish between the arterial, capillary, and venous compartments of the cerebral
circulation and thus reflect a weighted average of Hb concentrations within these
different blood compartments in the region sampled. The relative distribution of
arterial, capillary, and venous compartments in the CBV is generally accepted to be
approximately 20%, 10%, and 70% respectively [69]. Assuming that the capillary
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concentration of HHb is the average of arterial and venous concentrations, the final
CBV distribution would equate to 25% arterial blood and 75% venous blood. There is
some acceptable variability (10%) in the ratio from individual to individual [119].
The second assumption is that the cerebral water concentration is known (85%),
which is used to calculate the differential pathlength of light. The water content of the
brain is known to be very stable, and has been shown to only increase by less than
one percent 24 h after hypoxia-ischemia in neonatal rats [120]. The final potential
limitation is the use of an exogenous contrast agent to measured CBF. The advantage
of using indocyanine green (ICG) is increased measurement precision compared to
CBF measurements obtained with the HbO2 tracer method [63]. However, ICG, like
all contrast agents, has the risk of causing allergic reactions, albeit fairly small [56,
57]. Therefore, the clinical use of this technique requires a careful consideration of
the risks versus the potential benefit.

5.2.2 Limitations of Assessing the Effectiveness of DPCPX
This study lacked independent measurements of the cerebral adenosine
concentration to verify an increase after HI. However, elevated adenosine
concentrations within the brain have been previously demonstrated in rats during
hypoxia [100], as well as in the blood plasma in patients during ischemia [121].
Another potential limitation is that the study did not include any measure of neuronal
damage, such as by Fluro-Jade staining [74, 122], to determine if the changes in
CMRO2 caused by DPCPX treatment would exacerbate brain injury. However, this

44

effect has been previously demonstrated [106]. Furthermore, the objective of this
study was to investigate the mechanisms controlling changes in cerebral energy
metabolism immediately following HI since an earlier study demonstrated a
correlation between early CMRO2 changes and the severity of HI [74]. This
correlation suggests that measuring CMRO2 by NIRS could help to identify newborns
at risk of developing HIE.

5.3 Future Work
5.3.1 Investigate Alternate Mechanisms Controlling CMRO2
Post-HI
As mentioned in the Discussion, there appears to be two competing
mechanisms that control CMRO2 after HI: adenosine and nitric oxide. It has been
suggested that these two mechanisms interact as elevated adenosine levels could
increase NOS [116], while other studies suggest that they act independently [123].
Due to the lack of in vivo evidence, however, how or if adenosine and nitric oxide
interaction remains to be verified. This is of potential interest for future work using
the current model of HI in piglets with the adenosine antagonist (DPCPX) and the
incorporation of a neuronal and inducible nitric oxide (synthase) inhibitor.

5.3.2 Clinical Implementation of NIRS
The NIRS measurements of CMRO2 were shown to be sensitive to a hypoxicischemic injury within the first couple of hours after reperfusion. Furthermore, NIRS
could be used as a safe, portable, complementary diagnostic tool to accurately predict
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the extent of brain injury incurred by hypoxia-ischemia and other neonatal brain
disorders. For example, the technique may have implications in the diagnosis of both
intraventricular hemorrhage and periventricular leukamalacia, which are common
forms of brain injury in preterm neonates, and each with hemodynamic and metabolic
sequelae [33]. Lastly, this technique has the potential to substantially benefit the
monitoring and care of critically ill and very low birth weight infants requiring
medical intervention. The appendix of this thesis refers to one recently completed
pilot study that successfully used this NIRS technique to assess cerebral perfusion and
metabolic changes in preterm newborns.

5.4 Conclusions
The most significant findings of the thesis are:
1. Post-HI cerebral energy metabolism is in part controlled by an adenosinemediated mechanism. Blocking the adenosine A1 receptor significantly
diminished the depression of CMRO2 and aEEG typically observed following
HI. This suppression of cerebral metabolism and electrocortical activity
following HI is most likely a neuroprotective response.

2. Both NIRS and EEG techniques can be applied simultaneously at the bedside
of sick newborns, which could help to improve the diagnosis of hypoxicischemic encephalopathy by providing early detection of those infants that
would benefit from therapy.
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APPENDIX A
The contents of this chapter have been adapted from the paper entitled “A near-

infrared spectroscopy study to assess the effects of Indomethacin on cerebral blood
flow and metabolic rate of oxygen in preterm infants”, in the process of publication in
the Journal of Pediatric Research by Arora R, Ridha M, et al.
Responsibilities: Acquisition and analysis of the majority of the data.

Introduction
The ductus arteriosus is a vascular structure within the heart that connects the
aorta to the pulmonary artery. This fetal structure normally closes spontaneously after
birth. However, in cases where the ductus remains open, known as patent ductus
arteriosus (PDA), it poses a greater risk for pulmonary edema, hemorrhage and
decreased perfusion and oxygen delivery to the organs, including the brain [124]. The
incidence of PDA is inversely correlated to birth weight and gestational age, with
approximately 40% of infants having a PDA who are below 1000 g or of a gestational
age less than 28 weeks [125, 126].
Treatment of PDA is commonly in the form of a non-steroidal antiinflammatory drug (NSAID). Two primarily used ones clinically are: indomethacin
and ibuprofen [127, 128]. These drugs act similarly by inhibiting the production of
prostaglandins, constricting the ductus arteriosus, which induces anatomical
remodeling and ultimately ductal closure. Both drugs have the same efficacies with
success rates ranging between 60 to 80% [129]. The only notable difference between
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the two drugs is the physiological side-effect of indomethacin as a vasoconstrictor,
which has been shown to reduce renal and cerebral perfusion. The latter effect is of
particular interest considering this is a patient population that is already at high risk of
brain injury. Thus alterations in cerebral hemodynamics as a consequence of PDA
treatment remains a concern [128], particularly if these reductions are large enough to
affect cerebral energy metabolism.
The objective of the present study was to measure cerebral blood flow (CBF),
oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen (CMRO2) in
preterm infants with a hemodynamically significant PDA who have been selected to
receive treatment with indomethacin. Measurements were obtained prior to and
immediately following the infusion of the first dose of the drug, which was part of a
standard three-dose (one dose per day) protocol. CBF was measured with the same
bolus-tracking NIRS technique using the light-absorbing dye indocyanine green
(ICG) as described in chapter 1 and 2.

Method
Preterm infants (GA< 30 weeks) with hemodynamically significant PDA
(diagnosed based on clinical indices) were enrolled in the study after obtaining
informed and written parental consent. All NIRS data were collected with a
continuous-wave, broadband (600-980 nm) system using two fiber-optic bundles, one
for light emission and the other for detection [66]. The ends of the fiber bundles were
held 3.5 cm apart using a custom-built holder that was strapped to the infant’s head to
position the probes over the frontoparietal region. Measurements of CMRO2, CBF
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and OEF were determined using the same second derivative spectroscopy technique
[130] described in Chapter 1 (Sections 1.7 and 1.8).
Pharmacological treatment of PDA followed the standard indomethacin
dosage schedule consisting of three doses of 0.2mg/kg, each separated by 24 hours,
infused intravenously over 30 min. Two NIRS data sets were acquired on the first day
of treatment, one approximately 5 min prior to the start of drug infusion and the other
immediately at the end of 30 min infusion. The acquisition period for each ICG run
was approximately 80 s. The tissue and arterial ICG concentration curves were
acquired simultaneously by NIRS and the DDG, respectively.

Results
Complete data sets (i.e., both NIRS and DDG data before and after first
treatment dose) were obtained from 8 infants. Figure 1 shows the individual pre- and
post-treatment values of CBF, CBV, OEF, and CMRO2. A general reduction in CBF
and CBV was observed as expected due to the known vasoconstricting effects of
indomethacin. A concurrent increase in OEF was found while CMRO2 displayed no
significant change. These observations were confirmed by the mean pre- and posttreatment values given in Table 1. Indomethacin caused a significant decrease in CBF
of 18% (p<0.025) and in CBV of 17% (p<0.02). There was a significant increase in
OEF of 29% (p<0.025), but the drug has no overall effect on CMRO2. The PDA was
closed in all eight cases after the three-dose regimen of indomethacin.
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Table 1: Clinical parameters and near-infrared spectroscopy measurements before and
after indomethacin infusion
Parameter

Pre

Post

MAP (mm Hg)

36.9 ± 2.7

38.7± 2.8

EtCO2
(mm Hg)

56.1 ± 2.4

56.0 ± 2.2

pH

7.28 ± 0.02

7.25 ± 0.01

Heart Rate
(beats/min)

152 ± 4

156 ± 3

SaO2 (%)

93.6 ± 1.9

93.0 ± 2.0

12.9 ± 1.3

10.6 ± 0.9*

2.05 ± 0.12

1.69 ± 0.09*

OEF

0.28 ± 0.03

0.36 ± 0.03*

CMRO2
(ml O2·100
g−1·min−1)

0.59 ± 0.06

0.65 ± 0.07

CBF
−1

−1

(ml·100g ·min )
CBV
−1

(mL·100 g )

Values are mean ± SE (n = 8). MAP: mean arterial blood pressure, EtCO2: end-tidal
carbon dioxide tension, CBF, cerebral blood flow; CBV, cerebral blood volume;
[HHb], tissue concentration of deoxy-hemoglobin; OEF, oxygen extraction fraction;
CMRO2, cerebral metabolic rate of oxygen
*Significant change with treatment (p < 0.05).
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Figure 1. Individual values of pre and post single indomethacin treatment of PDA
for (a) cerebral blood flow (CBF), (b) cerebral blood volume (CBV), (c) oxygen
extraction fraction (OEF), and (d) the cerebral metabolic rate of oxygen (CMRO2) (n
= 8, 0.2 mg/kg). Data from each patient are represented by the same symbol and greyscaled line in all graphs.
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Discussion
The principle finding of this study was that, despite the significant reductions
in CBF and CBV caused by a 30-min infusion of indomethacin, there was no change
in CMRO2. In general, this finding was expected considering that under normal
conditions CMRO2 should remain stable during relatively moderate reductions in
CBF due to a compensatory increase in OEF. In this study the approximate 20%
reduction in CBF was accompanied by a statistically significant increase in OEF of
29% under indomethacin. It is only when the reduction in CBF is sufficient to impede
the supply of oxygen to the brain that CMRO2 is expected to be affected [131]. These
results suggest that, even at this very early age, the cerebral oxygen supply is
sufficient to accommodate moderate variations in cerebral perfusion. To the best of
our knowledge this study is the first to report quantitative measurements of CBF and
CMRO2 in infants obtained using ICG as a contrast agent. These results suggest that
this methodology could be used for beside assessments with other clinical conditions
that have the potential to affect cerebral hemodynamics and energy metabolism.
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